National Institutes of Health logo
National Institutes of Health

Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks

Funds research on whether HIV immunotherapies reach and calm the brain's viral reservoir without causing neurological harm.

Between cyclesNational Institutes of HealthUnited States

Treating HIV in the blood does not necessarily treat it in the brain. This notice funds finding out what immunotherapies do once they cross that line.

The work is biphasic, evaluating the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV, and identifying the mechanisms, benefits and risks of using them in the CNS compartment specifically.

The primary goal …

Biphasic research evaluating the impact of HIV immunotherapies on central nervous system outcomes in people with HIV, identifying mechanisms, benefits and risks in the CNS compartment — including blood-brain barrier penetration, compartmentalised viral dynamics and immune-mediated effects — toward sustained virologic remission and improved neurologic and cognitive outcomes.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.22 Oct 2026
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.—
Funding pooliThe total budget available across all awards in this round.$2M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: RFA-MH-27-110Source: www.grants.gov